1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. Pennsylvania >
  6. Galapagos Acquires AboundBio

M&A Deal Summary

Galapagos Acquires AboundBio

On June 22, 2022, Galapagos acquired life science company AboundBio for 14M USD

Acquisition Highlights
  • This is Galapagos’ 8th transaction in the Life Science sector.
  • This is Galapagos’ 5th largest (disclosed) transaction.
  • This is Galapagos’ 2nd transaction in the United States.
  • This is Galapagos’ 1st transaction in Pennsylvania.

M&A Deal Summary
Date 2022-06-22
Target AboundBio
Sector Life Science
Buyer(s) Galapagos
Deal Type Add-on Acquisition
Deal Value 14M USD

Target

AboundBio

Pittsburgh, Pennsylvania, United States
AboundBio is a privately held biotechnology company generate novel antibody-based biological therapeutics for cancers of unmet medical need. AboundBio is based in Pittsburgh, Pennsylvania.

Search 215,029 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Galapagos

Mechelen, Belgium
Category Company
Founded 1999
Sector Life Science
Employees683
Revenue 276M EUR (2024)
DESCRIPTION

Galapagos is a clinical stage biotech company focused on developing novel mode of action medicines. Galapagos was incorporated in 1999 and is based in Mechelen, Belgium.

DEAL STATS #
Overall 9 of 9
Sector: Life Science M&A 8 of 8
Type: Add-on Acquisition M&A Deals 4 of 4
State: Pennsylvania M&A 1 of 1
Country: United States M&A 2 of 2
Year: 2022 M&A 2 of 2
Size (of disclosed) 5 of 5
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-06-22 CellPoint

Oegstgeest, Netherlands

CellPoint is a developer of proprietary xCellit real-time monitoring software system, generating clinical data to validate decentralized manufacturing supply model with CD19 CAR-T for rrNHL/rrCLL. CellPoint is based in Oegstgeest, Netherlands.

Buy $125M
Mergr

Solution for

Product

Company

Legal